Opinion|Videos|April 4, 2025
Payer and Reimbursement Considerations for Bispecific Therapies
Experts discuss how payer and reimbursement considerations affect access to bispecific therapies in different practice settings.
Advertisement
Video content above is prompted by the following:
How do payer and reimbursement considerations affect access to bispecific therapies in different practice settings?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Metabolic Issues More Common in Patients With HIV
3
Iron Dysregulation Linked to MS Progression, Review Finds
4
Efficacy of Ruxolitinib Cream in Nonsegmental Vitiligo Confirmed in Real-World Study
5